Search Results for: CLINICAL TRIALS Its Time to
Articles
Atossa Therapeutics & Quantum Leap Healthcare Announce Clinical Trial to Evaluate (Z)-Endoxifen in Combination With Abemaciclib in Women With ER+/HER2- Breast Cancer April 16, 2024
Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative recently announced the initiation of a new study to evaluate Atossa’s proprietary...Neurona Therapeutics Presents Positive Clinical Update From Cell Therapy Trial in Adults With Drug-Resistant Focal Epilepsy April 15, 2024
Neurona Therapeutics presented updated preliminary data from its ongoing open-label Phase 1/2 clinical trial of NRTX-1001 in adults with drug-resistant,...AviadoBio Announces First Patient Treated in Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia With GRN Mutations April 15, 2024
AviadoBio recently announced the first patient has been treated in the Phase 1/2 ASPIRE-FTD trial evaluating AviadoBio’s investigational gene therapy,...Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits From Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer March 21, 2024
Nykode Therapeutics ASA recently announced key conclusions from the updated analysis from the Phase 2 VB-C-02 trial. The trial investigates...ACELYRIN Announces Positive Phase 1/2 PoC Data for First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease March 20, 2024
ACELYRIN, INC. recently announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously….
RespireRx Pharmaceuticals Reports Preclinical Research Demonstrating the Ability of its Lead Clinical AMPAkine to Improve Bladder Function After Spinal Cord Injury March 20, 2024
RespireRx Pharmaceuticals Inc. recently announce that, as part of an ongoing collaboration, a scientist team led by Dr. David Fuller...Acelyrin Announces Positive Top-line Results From Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis March 11, 2024
ACELYRIN, INC. recently announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint...DRUG DELIVERY - EUDRACAP® Select - Examining a Case From Development to Clinical Trial February 29, 2024
Lucas Paulo Cusin, Kamlesh Oza, PhD, and Steven Smith, et al focus on the development of a customized functional coated capsule for the delivery of live biotherapeutics and demonstrate its effectiveness in the oral delivery of a sensitive proprietary microbiome ecosystem while simplifying the drug development process.
PREFILLED SYRINGES - Making a Prefilled Syringe Smart: Technological Solutions to Advance Patient Care & Clinical Trial Outcomes February 29, 2024
Salvatore Forte, MS, believes adherence to the dosing regimen, as well as compliance to the injection protocol, are essential for treatment success in both these use-cases. Hence, the request for a connected, smart PFS is growing just as much to tackle poor medication adherence and compliance issues.
CLINICAL TRIALS - Digital Endpoint Integration in Clinical Trials: Key Considerations & Nuances Per Therapeutic Focus February 29, 2024
Tapan Raval and Ganesh Gundi, MD, say enhancing the patient experience and reducing burden is key in today’s drug development landscape, and DHTs can certainly play a positive role in that.
MAIA Biotechnology Completes Enrollment in Phase 2 Clinical Trial for Non-Small Cell Lung Cancer February 22, 2024
MAIA Biotechnology, Inc. recently announced enrollment is now complete in its Phase 2 THIO-101 go-to-market clinical trial evaluating THIO sequenced...Mestag Therapeutics Enlists Leading Cancer Biology & Immunology Advisors to Support Clinical Development of its Lead Oncology Program February 20, 2024
Mestag Therapeutics recently announced the appointments of additional distinguished, world-leading advisors to guide the development of its lead program M300,...Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published February 15, 2024
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys…..
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections January 30, 2024
Iterum Therapeutics plc recently announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial...CLINICAL TRIALS - The Power of AI in Overcoming Patient Diversity Challenges January 26, 2024
Isaac Bentwich, PhD, explores why patient diversity is such a challenge for clinical trials, where that pain is often felt the most, some of the regulatory, technological, and industry changes already underway to solve the clinical trial gap, and where AI changes the future of patient diversity.
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as CRO to Support First-in-Human Study January 8, 2024
Artelo Biosciences, Inc. recently announced it has selected Worldwide Clinical Trials to support the its planned Phase 1 trial with...TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint0Resistant Metastatic Melanoma Phase 1 Trial December 8, 2023
TILT Biotherapeutics recently presented safety and efficacy data from its international Phase 1 trial in patients with metastatic melanoma (NTC04217473),...Incannex Provides Update on Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea December 6, 2023
Incannex Healthcare Inc. recently provided the following update on its proprietary IHL-42X drug candidate. Obstructive sleep apnea (OSA) is characterized...Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human SQ Dosing Option for Patients With Alpha1-Antitrypsin Deficiency November 15, 2023
Grifols recently announced it has completed Cohort 1 of its Phase 1/2 study (NCT04722887) evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15%...Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD November 1, 2023
Ocular Therapeutix, Inc. recently announced it had received written agreement regarding the overall design from the US FDA under a...
